News

Empty gabapentin capsules spur recall


 

References

Following the discovery of capsules found to be empty, Aurobindo Pharma USA has initiated a recall of the epilepsy treatment gabapentin, the company announced Nov. 21.

The company is voluntarily recalling lot GESB14011-A of 100-count bottles of 300 mg gabapentin, which have an expiration date of December 2015. The product also is used to manage postherpetic neuralgia.

The Food and Drug Administration noted that the empty capsules could result in missed doses, potentially resulting in no effect, short-term efficacy reduction, short-term withdrawal effect, or status epilepticus that could be life threatening.

gtwachtman@frontlinemedcom.com

Recommended Reading

Hydrocodone rescheduling takes effect Oct. 6
MDedge Emergency Medicine
Risk factors outweigh benefits of opioids for chronic noncancer pain
MDedge Emergency Medicine
More docs need to use available Rx-monitoring programs to help curb opioid abuse
MDedge Emergency Medicine
Curbing opioid abuse could be a quality of care issue
MDedge Emergency Medicine
FDA approves new abuse-prevention labeling for extended-release Embeda
MDedge Emergency Medicine
Prescription opioids linked to majority of opioid overdoses
MDedge Emergency Medicine
High-dose opioids mainly prescribed in offices, not the ED
MDedge Emergency Medicine
NSAIDs linked to serious bleeding, thromboembolism in AF patients
MDedge Emergency Medicine
Topiramate
MDedge Emergency Medicine
FDA approves extended-release hydrocodone with abuse-deterrent features
MDedge Emergency Medicine